• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

The Weekly Roundup: October 29-November 3


ICYMI, this week we had articles about World Psoriasis Day, the FDA approval of secukinumab for hidradenitis suppurativa, positive data of delgocitinib cream for chronic hand eczema, and more.

World Psoriasis Day Highlights Advocacy, Awareness, and Education

Leah Howard, JD, of the National Psoriasis Foundation, discusses the importance of advocacy in psoriasis, the role of mental health in chronic skin conditions, and the role of support organizations in advocating for awareness and health equity.

Study Reveals HCPs Underestimate Burden of Disease Associated With Seborrheic Dermatitis

The study was presented in a poster at the 2023 SDPA Fall Conference in Nashville, TN.

Understanding Itchy Dermatoses: Pearls and Best Practices

Ted Rosen, MD, presented a session comprehensively discussing common dermatoses characterized by itch and pruritus.

Mark Lebwohl, MD: The Evolving Treatment Landscape of IL-17 Inhibitors

Mark Lebwohl, MD, spoke with Dermatology Times about his talk on IL-17 inhibitors.

Individualized Treatment Considerations for Adult Women With Acne

Allison Arthur, MD, discussed the importance of tailoring a treatment plan for adult women with acne vulgaris that best suits their lifestyle and current needs.

2023 SDPA Fall Conference Recap: Day 4

Catch up on coverage from the fourth and final day of the 2023 SDPA Fall Dermatology Conference.

Eczema Resources for Your Patients: Monthly Recap

Review the full list of eczema resources for your patients shared during National Eczema Awareness Month.

POLL: What Did You Take Away From SDPA Fall 2023?

Click here to answer today's poll.

Recap From the 2023 SDPA Annual Fall Conference

If you weren’t able to attend the 2023 Society of Dermatology Physicians Fall Conference or want to review our latest coverage and interviews, our full recap has you covered.

Revolutionizing Scabies Care With Artificial Intelligence

A new AI platform empowers health care practitioners in numerous specialties to make informed decisions and provide high-quality care to patients with scabies.

The Impact of Nature-Based Products on Skin Health

From reducing age spots to nurturing the lip microbiome and supporting sensitive skin, 3 studies presented at the 2023 Integrative Dermatology Symposium highlighted the transformative potential of botanicals in skin care.

FDA Approves Secukinumab for Hidradenitis Suppurativa

Secukinumab is currently the only IL-17A inhibitor approved for the condition.

Discovering Dermatology Times: October 2023

Learn more about the in-depth topics covered in the October 2023 print issue of Dermatology Times.

Assessing Treatment Response in Patients With Vitiligo

Susan C. Taylor, MD, and George Han, MD, PhD, discuss how to measure treatment response in patients with vitiligo and share advice for counseling patients about long-term use and compliance of treatment.

Overcoming Barriers to Access for Vitiligo Treatment

Experts in dermatological conditions provide insight on challenges patients and clinicians may face in accessing vitiligo medications, especially for newer therapies, and the future of vitiligo treatment.

AI-Based Color Constancy Algorithm Improves Dermoscopy, Clinical Care

A comparative study revealed that color constancy algorithms reduce the variability of dermoscopy image quality, leading to positive outcomes for practitioners.

ChatGPT Performs Well in Actinic Keratosis Pathogenesis and Risk Factor Knowledge, Lacks in Diagnosis and Treatment

ChatGPT shows promise in dermatology but needs improvement in accuracy and conciseness for reliable clinical use, according to a study evaluating its performance in actinic keratosis management.

Case 1: Female, 28-Years-Old

Ted Lain, MD & MBA, FAAD, provides an overview of a dinner discussion centered around a challenging case of a 28-year-old female experiencing recurrent flaring atopic dermatitis. He shares insights from a panel of dermatologists regarding their recommended treatment approach, emphasizing the incorporation of a novel topical treatment to achieve enduring disease remission.

Case 2: Male, 58-Years-Old

An expert in dermatology presents the case of a 58-year-old male who has struggled with long-standing atopic dermatitis. The presentation delves into the considerations between topical and systemic treatments and sheds light on the intricacies of managing patients with comorbidities, extensive treatment histories, and the challenges posed by prior authorizations.

FDA Approves Ustekinumab-auub as Interchangeable Biosimilar to Stelara for Plaque Psoriasis, Psoriatic Arthritis, and More

The approved indication makes Wezlana the first approved interchangeable biosimilar to Stelara.

Pointers With Portela: Hair Transplant Risks

In this week’s Pointers With Portela, the 208SkinDoc explains the hidden risks associated with hair transplants.

Review Finds Topical Erythromycin, Azithromycin, and Metronidazole Most Common Treatments for Pediatric Rosacea

Additionally, investigators found that several patients in the review had rosacea induced or exacerbated by the use of topical corticosteroids on the face.

POLL: Do You Utilize the 40-GEP Test for High Risk cSCC?

Click here to answer this week's skin cancer poll.

Lebrikizumab Maintains Skin Clearance for 2 Years in Atopic Dermatitis

Almost 80% of patients in an extension study maintained clear or almost clear skin, and 90% of patients saw continued improvements in itch.

Patient With Plaque Psoriasis and Accompanying End-Stage Renal Disease Treated With Adalimumab

Authors of the case report that little is known about the associations between psoriasis and renal function.

Long-Term Safety of Dupilumab in Adults with Moderate to Severe Atopic Dermatitis

The results from this 5-year open-label extension trial affirm the safety of dupilumab in adults with moderate to severe AD.

LEO Pharma Announces Positive Results for Delgocitinib Cream for Chronic Hand Eczema

Delgocitinib is first-in-class pan-Janus kinase inhibitor.

Proteomic Analysis Reveals Potential Differences in Patients Achieving VASI 50 Improvements VS Those Who Do Not

Investigators believe different circulating inflammatory phenotypes in patients with vitiligo may influence their responses to treatment with ruxolitinib cream.

Psoriasis Patients With Pruritis, Sleep Impairments Demonstrate Lower Quality of Life in All Domains

PASI scores were significantly correlated with sleep quality, duration, and disturbances.

Acne Survey Reveals 3 in 10 Patients Have Not Gone to a Dermatologist for Treatment

The Sun Pharma survey included 1003 respondents with mild to moderate acne.

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Recent Videos
© 2024 MJH Life Sciences

All rights reserved.